Search Videos and More
News
New Protein Complex Structure Reveals Possible Ways To Target Key Cancer Pathway
Scientists have solved the structure of an important complex of RAS-pathway proteins, explaining how known mutations lead to disease and suggesting potential new binding sites for cancer drugs.
Symposium
ASCO 2022: GU Highlights
In the following videos, faculty from Dana-Farber Cancer Institute review GU Oncology highlights from the 2022 ASCO Annual Meeting, held in Chicago, June 3-7, 2022.
Symposium
The Young-Onset Colorectal Cancer Center’s Gut Instincts Series
The Young-Onset Colorectal Cancer Center’s Gut Instincts Series is a quarterly webinar for healthcare professionals to learn more about colorectal cancer and the unique challenges individuals diagnosed under the age of 50 face. Events are hosted by Young-Onset Colorectal Cancer Center Director Dr. Kimmie Ng and include a panel of medical experts and a patient perspective.
News
Dana-Farber Researchers Launch New Project to Investigate How Neighborhoods Contribute to Prostate Cancer Inequity
Researchers at Dana-Farber Cancer Institute and the Rutgers University Cancer Institute are investigating what it is about neighborhoods that may increase a Black man’s risk of dying from prostate cancer.
News
FDA Approves New Treatment Option For Glioma
The U.S. Food and Drug Administration’s accelerated approval of a two-drug therapy for solid tumors carrying a specific mutation in the BRAF gene is a prime example of this trend. For patients with glioma brain cancer that harbors the mutation, the ruling is a landmark.
News
Study Shows That Genomic Tumor Profiling of Pediatric Tumors Can Enhance Clinical Care
Results of a study of molecular tumor profiling in young patients revealed a high rate of genetic alterations with potential for impacting clinical care, including clarifying diagnoses and treatment with matched, precision cancer drugs.
News
Study Finds Breast Cancers with Low Levels of HER2 Protein Are Not a Distinct Subtype of the Disease
When researchers discovered that breast cancers with lower levels of HER2 often respond to a trastuzumab-and-chemotherapy drug conjugate, they wondered whether such tumors represent a distinct subtype of breast cancer, with its own unique behavior and prognosis.
Symposium
2022 ASCO Highlights
Review highlights of key advances in cancer research and an overview of Dana-Farber faculty presentations.
News
Dana-Farber/Boston Children's Again Named Top Pediatric Cancer Program
U.S. News & World Report has named Dana-Farber/Boston Children's Cancer and Blood Disorders Center #1 in the nation in its 2022-23 Best Children's Hospitals report. Dana-Farber/Boston Children's has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking's inception, earning more #1 rankings than any other program.
Video
Marla Lipsyc-Sharf, MD on ctDNA in Breast Cancer
Using ctDNA found with liquid biopsy to understand recurrence risk in hormone receptor-positive breast cancer: Dana-Farber's Marla Lipsyc-Sharf MD, details research presented at #ASCO22 and published in the Journal of Clinical Oncology.
News
Improved Progression-Free Survival in Patients with Multiple Myeloma Following Three-Drug Therapy with Autologous Stem Cell Transplant
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
News
Targeted Drug Achieves 43% Response Rate in KRAS-Mutated Lung Cancer
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a study led by Dana-Farber Cancer Institute investigators.